Volume | 1,310,994 |
|
|||||
News | (1) | ||||||
Day High | Low High |
||||||
Day Low |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Akebia Therapeutics Inc | AKBA | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
2.24 |
Trades | Volume | Avg Volume | 52 Week Range |
---|---|---|---|
6,845 | 1,310,994 | - | 0.4901 - 2.335 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
04:30:48 | formt | 600 | $ 2.75 | USD |
Akebia Therapeutics (AKBA) Options Flow Summary
Akebia Therapeutics Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
468.99M | 209.37M | - | 292.6M | -92.56M | -0.44 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Akebia Therapeutics News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical AKBA Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.96 | 2.335 | 1.91 | 2.13 | 8,568,369 | 0.79 | 40.31% |
1 Month | 1.58 | 2.335 | 1.34 | 1.85 | 5,302,080 | 1.17 | 74.05% |
3 Months | 1.38 | 2.335 | 1.29 | 1.71 | 3,260,943 | 1.37 | 99.28% |
6 Months | 1.18 | 2.335 | 0.7801 | 1.49 | 2,267,325 | 1.57 | 133.05% |
1 Year | 0.6401 | 2.335 | 0.4901 | 1.35 | 1,997,439 | 2.11 | 329.62% |
3 Years | 3.10 | 4.33 | 0.241 | 1.35 | 3,673,001 | -0.35 | -11.29% |
5 Years | 8.46 | 13.78 | 0.241 | 2.48 | 3,394,014 | -5.71 | -67.49% |
Akebia Therapeutics Description
Akebia Therapeutics Inc is a biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics to patients with kidney disease through hypoxia-inducible factor (HIF) biology. Its lead product candidate is Vadadustat, an oral therapy, which is used for the treatment of anemia related to chronic kidney disease in non-dialysis and dialysis patients. The company is also developing a HIF-based portfolio of product for the treatment of anemia. Geographically, all the business activity is functioned through the region of United States. |